Cargando…
Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medicatio...
Autores principales: | Dokmak, Amr, Almeqdadi, Mohammad, Trivedi, Hirsh, Krishnan, Sandeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669193/ https://www.ncbi.nlm.nih.gov/pubmed/31388398 http://dx.doi.org/10.4254/wjh.v11.i7.562 |
Ejemplares similares
-
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
por: Zhang, Enxiang, et al.
Publicado: (2021) -
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2020) -
Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
por: Yano, Kota, et al.
Publicado: (2020) -
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Euh, Won, et al.
Publicado: (2021) -
Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
por: Saha, Arunava, et al.
Publicado: (2022)